Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 Dosing Study in mCRPC
NCT02023697Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2014
- Primary completion
- Mar 2017
- Modality
- Radiopharmaceutical
- Countries
- 15
01
Overview
A Phase 2 trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by Bayer. Started Mar 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02023697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023697.